肿瘤细胞治疗研究
FRONTIER PAPERS
Amivantamab Induces Immune-Mediated Cytotoxicity in Mesothelioma Through EGFR and MET Engagement.
Amivantamab 在间皮瘤中表现出强大的临床前抗肿瘤活性，主要通过与 EGFR 和 MET 结合相关的固有免疫介导的细胞毒性。这些发现支持在间皮瘤中对双特异性 EGFR/MET 靶向抗体进行临床评估。
Multi-omics analysis reveals differential benefits of immunotherapy±chemotherapy based on detailed smoking history in advanced non-small cell lung can
详细的吸烟史通过肿瘤微环境和全身血浆蛋白谱的机制性改变，为优化晚期 NSCLC 的 IO 选择提供了关键见解。
The Activity of EGFR CAR NK and CAR T Cells against EGFR Inhibitor-Resistant NSCLC and Drug-Tolerant Persister Cells.
靶向 EGFR 的细胞疗法，尤其是 EGFR CAR NK 细胞，在体外和体内对 EGFR 突变型 DTPC 和 DRC 显示出活性，与 EGFR TKI 或 TGF- 通路阻断联合时活性增强。
Eradicating Drug-tolerant Persister Cells in EGFR-Mutated Non-Small Cell Lung Cancer by Targeting TROP2 with CAR-T Cellular Therapy.
Chimeric TIM-4 receptor-modified T cells targeting phosphatidylserine mediates both cytotoxic anti-tumor responses and phagocytic uptake of tumor-asso
IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC.
这些数据表明，在获得性 EGFR-TKI 耐药的 EGFR 突变非小细胞肺癌（NSCLC）肿瘤中，IL6 表达上调并抑制 T 细胞和 NK 细胞功能。
CD70 is a therapeutic target upregulated in EMT-associated EGFR tyrosine kinase inhibitor resistance.
Tumor cell SYK expression modulates the tumor immune microenvironment composition in human cancer via TNF-α dependent signaling.
我们的结果确立了 SYK 表达在人类实体瘤中的免疫调节作用。这些信息可用于开发新型生物标志物和/或治疗策略。
MET Amplification Attenuates Lung Tumor Response to Immunotherapy by Inhibiting STING.
A dual diacylglycerol kinase (DGK) alpha/zeta inhibitor augments the activity of human tumor infiltrating lymphocytes in in vivo and ex vivo models.
MEMBER ACCOUNT
登录成功会直接打开下一页。
